Search academic texts

Information × Registration Number 0213U001019, 0110U000179 , R & D reports Title Complex estimation of the target therapy efficiency in patients with chronic myeloid leukemia taking into consideration immunogenetic, cytogenetic and molecular genetic features of cell's pathological clones popup.stage_title Head Dyagil I.S., Registration Date 09-01-2013 Organization State institution "National research centеr for radiation medicine of the National academy of medical sciences of Ukraine " popup.description2 To determine the contribution of cytogenetic, molecular genetic, immunogenetic components to assessment of the effectiveness of tyrosine kinase inhibitors therapy in patients with chronic myeloid leukemia were examined 168 patients with CML, of them 91 woman, 77 men are in age from 18 to 65 years. Among examinated patients with CML three men suffered from Chernobyl power plant accident consequences. It was determined that follow factors impact the formation of the optimal and suboptimal response on therapy: risk group according international prognostic indexes and pretreatment duration before beginning of imatinib. In patients who received imatinib therapy 6 months, the optimal response was registered in 46,6%. After 12 month of treatment in 30.3% cases optimal response was obtained. It was established that the appearance of additional chromosome abnormalities (especially additional Ph-chromosome) in Ph+ bone marrow cells during imatinib therapy has statistical significant unfavorable prognostic value for forming major and complete cytogenetic response. Patient with expression of transcript b2a2 more often remained optimal response. Secretion level of proleukemic and antileukemic cytokines could be a monitoring means of TKI therapy response in patients with CML on different stages of treatment. In patients with CML significant increasing of carriage of genes HLA-B*51 and HLA-DRB1*11 were determined. It gives reason to consider them as genetic factors of susceptibility to this disease. Genes-protectors of chronic myeloid leukemia: HLA-A*3, HLA-B*08 and HLA-DRB1*04 were established. There were qualitative and quantitative features of palmar relief and dactylar patterns specific for CML. Reduced efficiency of progenitor cells colony-formation , the predominance of small clusters in the bone marrow culture and reduction of the colony-formation ability of fibroblasts indicate specific inhibition of bone marrow cells proliferation in patient with CML who treated with imatinib. Complex of prognostic tests for assessment of CML course. The optimization algorithm for target therapy with application of bone marrow transplantation was worked out. Product Description popup.authors Бєлінська Ірина Володимирівна Балан Валентина Володимирівна Дмитренко Ірина Віталіївна Дмитренко Олена Олександрівна Кучер Олена Володимирівна Мішаріна Жана Анатоліївна Малінкіна Т.В. Федоренко Віра Григорівна Шляхтиченко Тетяна Юрівна Шолойко Валентина Василівна popup.nrat_date 2020-04-02 Close